A quantitative approach to early rheumatoid arthritis

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 2, 2011, Pages 116-121

  Huizinga, Tom W J ^a   van der Helm van Mil, Annette ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DR ANTIGEN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RHEUMATOID FACTOR; STROMELYSIN;

ARTHRITIS; ARTICLE; BODY MASS; CLINICAL ASSESSMENT TOOL; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG EFFICACY; FAMILY HISTORY; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEREDITY; HUMAN; INCIDENCE; JOINT DESTRUCTION; JOINT SWELLING; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE DRUG DOSE; SMOKING; SYNOVITIS; TREATMENT DURATION; UNDIFFERENTIATED ARTHRITIS;

ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; REMISSION, SPONTANEOUS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC; TIME FACTORS;

EID: 79960459576     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. van Nies JA, de Jong Z, van der Helm-van Mil AH, et al. Improved treatment strategies reduce the increased mortality risk in early RA patients. Rheumatology (Oxford). 2010 Nov;49(11):2210-6; Epub 2010 Aug 9.
2. Puolakka K, Kautiainen H, Pohjolainen T, Virta L. No increased mortality in incident cases of rheumatoid arthritis during the new millennium. Ann Rheum Dis. 2010 Nov;69(11):2057-8.
3. van Schaardenburg D, Nielen MM, Lems WF, et al. Bone metabolism is altered in preclinical rheumatoid arthritis. Ann Rheum Dis. 2010 Oct 18; Epub ahead of print.
4. Turesson C, Bergström U, Jacobsson LT, et al. Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis. Ann Rheum Dis. 2011 Mar;70(3):520-2; Epub 2010 Nov 15.
5. Dougados M, Jousse-Joulin S, Mistretta F, et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis. 2010 May;69(5):828-33.
6. van Aken J, van Bilsen JH, Allaart CF, et al.The Leiden Early Arthritis Clinic. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S100-5.
7. Hulsemann JL, Zeidler H. Undifferentiated arthritis in an early synovitis out-patient clinic. Clin Exp Rheumatol. 1995;13(1):37-43.
8. van der Linden MP, Knevel R, Huizinga TW, et al. Classification of rheumatoid arthritis - comparison of the 1987 ACR and 2010 ACR/EULAR criteria. Arthritis Rheum. 2010 Oct 21; Epub ahead of print.
9. de Rooy DP, van der Linden MP, Knevel R, et al. Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011 Jan;50(1):93- 100; Epub 2010 Jul 16.
10. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum. 2005 Oct;52(10):3058-62.
11. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006 Apr;54(4):1117-21.
12. Linn-Rasker SP, Allaart CF, Kloppenburg M, et al. Sustained remission in a cohort of patients with RA: association with absence of IgM-rheumatoid factor and absence of anti-CCP antibodies. Int J Advances Rheumatology. 2004:2(4):4-6.
13. van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009 Aug;60(8):2262-71.
14. van Aken J, van Dongen H, le Cessie S, Allaart CF, et al. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis. 2006 Jan; 65(1):20-5; Epub 2005 May 18.
15. Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46:625-31.
16. van der Helm-van Mil AH, Toes RE, Huizinga TW. Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis. 2010 Sep;69(9):1694-6.
17. Syversen SW, Landewe R, van der Heijde D, et al. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. J Rheumatol. 2009;36(8):1769-84.
18. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term effect of early treatment on radiographic progression in rheumatoid arthritis; a meta analysis. Arthritis Rheum. 2006;55(6):864-72.
19. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease modifying antirheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43(7):819-20.
20. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S154-7.
21. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997 Feb;40(2):217-25.
22. Willemze A, Ioan-Facsinay A, El-Gabalawy H. Anti-citrullinated protein antibody response associated with synovial immune deposits in a patient with suspected early rheumatoid arthritis. J Rheumatol. 2008 Nov;35(11):2282-4.
23. van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of early arthritis patients. Arthritis Rheum 2010 Aug 18; Epub ahead of print.
24. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46:894-98
25. Green M, Marzo-Ortega H, McGonagle D, et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum. 1999;42(10):2184-8.
26. van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 2007;56(2):433-40.
27. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46(2):357-65.
28. van der Helm-van Mil AH, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 2008;58(8):2241-47.
29. Kuriya B, Cheng CK, Chen HM, Bykerk VP. Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis. Ann Rheum Dis.2009;68(9):1482-5.
30. Tamai M, Kawakami A, Uetani M, et al. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. Arthritis Rheum. 2009;61(6):772-8.
31. Bradna P, Soukop T, Bastecj D, Hrncir J. Prediction rule in early and very early arthritis patients. Ann Rheum Dis 2009;68(Suppl 3): 547.
32. Luchikhina El, Karateev DE, Nasonov EL. The use of prediction rule to predict the development of rheumatoid arthritis in russian patients with early undifferentiated arthritis Ann Rheum Dis. 2008;58:2241-7.
33. Mjaavatten MD, Van der Helm-van Mil AH, Huizinga TW, Nygaard H, Haugen AJ, Helgeveit K, et al. Validation of a proposed prediction rule for rheumatoid arthritis in a cohort of 188 patients with undifferentiated arthritis. Ann Rheum Dis. 208l 67(Suppl II):477.
34. Aletaha D, Neogi T, Silman AJ, et al; American College of Rheumatology; European League Against Rheumatism. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatismcollaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.
35. Machold KP, Landewé R, Smolen JS, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis. 2010;69(3):495-502.
36. Verstappen SM, McCoy MJ, Roberts C, et al; STIVEA investigators. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis. 2010;69(3):503-9. Epub 2009 Oct 12.
37. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56(5):1424-32.
38. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69(3):510-6.
39. Saleem B, Mackie S, Quinn M, et al. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? Ann Rheum Dis. 2008;67(8):1178-80.